April 29, 2026

Optogenetic RP Therapy Gains RMAT

Ray Therapeutics secures FDA RMAT designation for its optogenetic retinitis pigmentosa therapy

The Ophthalmologist

April 24, 2026

Hydrus®: The Long-Term Evidence

Professor Gus Gazzard* outlines the five-year results of the HORIZON study, evaluating the safety and efficacy of the Hydrus® Microstent

The Ophthalmologist

April 23, 2026

AAO Updates HCQ Retinopathy Guidance

Updated recommendations emphasize dosing limits and screening for toxicity risk.

Conexiant

April 22, 2026

Permanent J-Code for Epioxa

Glaukos secures permanent J-code from CMS ahead of July rollout

The Ophthalmologist

April 20, 2026

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy

Conexiant

April 20, 2026

Closing Communication Gaps in Eye Care

Study findings highlight communication barriers in ophthalmology and outline a structured framework designed to support understanding, expectation-setting, and adherence.

Conexiant

April 17, 2026

Retinal Imaging Model Aids CAD Detection

Fundus-based model showed moderate-to-good accuracy and improved performance when combined with clinical risk factors in a high-risk cohort

Conexiant

April 16, 2026

AI Supports Glaucoma Surgical Planning

Predictive models identify high-risk patients and support earlier treatment decisions.

Conexiant

April 15, 2026

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.

Conexiant

April 13, 2026

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Conexiant